Cited by 405Cannabis and Cannabinoid ResearchNeurotransmitter Receptor Influence on BehaviorNicotinic Acetylcholine Receptors Study

The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.

SR141716, a central cannabinoid (CB1) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats

Cohen, C., Perrault, G., Voltz, C., Steinberg, R., Soubrié, P.·2002·Behavioural Pharmacology

DOI 10.1097/00008877-200209000-00018

Open this paper in CoChat — free account

Abstract

The central CB(1) cannabinoid receptor has recently been implicated in brain reward function. In the present study we evaluated first the effects of the selective CB(1) receptor antagonist, SR141716, on the motivational effects of nicotine in the rat. Administration of SR141716 (0.3 and 1 mg/kg) decreased nicotine self-administration (0.03 mg/kg/injection). SR141716 (0.3-3 mg/kg) neither substituted for nicotine nor antagonized the nicotine cue in a nicotine discrimination procedure, but dose-dependently (0.01-1 mg/kg) antagonized the substitution of nicotine for D-amphetamine, in rats trained to discriminate D-amphetamine. Secondly, using brain microdialysis, SR141716 (1-3 mg/kg) blocked nicotine-induced dopamine release in the shell of the nucleus accumbens (NAc) and the bed nucleus of the stria terminalis. To investigate whether SR141716 would block the dopamine-releasing effects of another drug of abuse, we extended the neurochemical study to the effect of ethanol, consumption of which in rodents is reduced by SR141716. Dopamine release induced by ethanol in the NAc was also reduced by SR141716 (3 mg/kg). These results suggest that activation of the endogenous cannabinoid system may participate in the motivational and dopamine-releasing effects of nicotine and ethanol. Thus, SR141716 may be effective in reduction of alcohol consumption, as previously suggested, and as an aid for smoking cessation.

Integrity signals

Registry

Crossref · 10.1097/00008877-200209000-00018

Cites

78 of 78 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Structure of a cannabinoid receptor and functional expression of the cloned cDNA
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990) · Nature · doi:10.1038/346561a0 · Cited by 5,011
What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience?
Berridge, K. C., & Robinson, T. E. (1998) · Brain Research Reviews · doi:10.1016/s0165-0173(98)00019-8 · Cited by 4,127
Unresponsiveness to Cannabinoids and Reduced Addictive Effects of Opiates in CB 1 Receptor Knockout Mice
Ledent, C. A., Valverde, O., Cossu, G., Petitet, F., Aubert, J.-F., Beslot, F., Böhme, G. A., Impérato, A., Pedrazzini, T., Roques, B. P., et al. (1999) · Science · doi:10.1126/science.283.5400.401 · Cited by 3,628
Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish
Gaoni, Y., & Mechoulam, R. (1964) · Journal of the American Chemical Society · doi:10.1021/ja01062a046 · Cited by 2,389
SR141716A, a potent and selective antagonist of the brain cannabinoid receptor
Rinaldi, M. L., Barth, F., Héaulme, M., Shire, D. J., Calandra, B., Congy, C., Martinez, S., Maruani, J., Neliat, G., Caput, D., et al. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)00773-x · Cited by 1,762
Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system
Tsou, K., Brown, S., Sañudo-Peña, M. C., Mackie, K., & Walker, J. M. (1998) · Neuroscience · doi:10.1016/s0306-4522(97)00436-3 · Cited by 1,586
The role of nucleus accumbens dopamine in motivated behavior: a unifying interpretation with special reference to reward-seeking
Ikemoto, S., & Panksepp, J. (1999) · Brain Research Reviews · doi:10.1016/s0165-0173(99)00023-5 · Cited by 1,450
Cannabinoid and Heroin Activation of Mesolimbic Dopamine Transmission by a Common µ 1 Opioid Receptor Mechanism
Tanda, G., Pontieri, F. E., & Chiara, G. D. (1997) · Science · doi:10.1126/science.276.5321.2048 · Cited by 1,085
Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs.
Pontieri, F. E., Tanda, G., Orzi, F., & Chiara, G. D. (1996) · Nature · doi:10.1038/382255a0 · Cited by 1,073
The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine
Corrigall, W. A., Franklin, K. B. J., Coen, K. M., & Clarke, P. B. S. (1992) · Psychopharmacology · doi:10.1007/bf02245149 · Cited by 829

Show all 77 references

Research works printed but not linked: 3

Cohen, 1999b, NIDA Research Monograph US Department of Health Human Services, 180, 197
deFonseca, 1999, Acta Pharmacol Sin, 20, 1109
De Vries, 2001, Nature, 7, 1511

Sorted by citations

The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
Endocannabinoid-Mediated Control of Synaptic Transmission
Kano, M., Ohno‐Shosaku, T., Hashimotodani, Y., Uchigashima, M., & Watanabe, M. (2009) · Physiological Reviews · doi:10.1152/physrev.00019.2008 · Cited by 1,595
The neurobiology and control of anxious states
Millan, M. J. (2003) · Progress in Neurobiology · doi:10.1016/s0301-0082(03)00087-x · Cited by 978
The mesolimbic dopamine system: The final common pathway for the reinforcing effect of drugs of abuse?
Pierce, R. C., & Kumaresan, V. (2006) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.04.016 · Cited by 913
Cannabinoid physiology and pharmacology: 30 years of progress
Howlett, A. C., Breivogel, C. S., Childers, S. R., Deadwyler, S. A., Hampson, R. E., & Porrino, L. J. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.07.030 · Cited by 608
Involvement of the endocannabinoid system in drug addiction
Maldonado, R. J., Valverde, O., & Berrendero, F. (2006) · Trends in Neurosciences · doi:10.1016/j.tins.2006.01.008 · Cited by 601
CANNABINOID RECEPTORS AS THERAPEUTIC TARGETS
Mackie, K. (2005) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.46.120604.141254 · Cited by 518
Endocannabinoid system and stress and anxiety responses
VIVEROS, M., MARCO, E., & FILE, S. (2005) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2005.01.029 · Cited by 485
From Phytocannabinoids to Cannabinoid Receptors and Endocannabinoids: Pleiotropic Physiological and Pathological Roles Through Complex Pharmacology
Ligresti, A., PETROCELLIS, L. D., & Marzo, V. D. (2016) · Physiological Reviews · doi:10.1152/physrev.00002.2016 · Cited by 505
Nicotine use in schizophrenia: The self medication hypotheses
Kumari, V., & Postma, P. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.02.006 · Cited by 470
The Endocannabinoid System: Drug Targets, Lead Compounds, and Potential Therapeutic Applications
Lambert, D. M., & Fowler, C. J. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm058183t · Cited by 354
Cannabinoid CB1 receptor knockout mice exhibit markedly reduced voluntary alcohol consumption and lack alcohol‐induced dopamine release in the nucleus accumbens
Hungund, B. L., Szakall, I., Ádám, Á., Basavarajappa, B. S., & Vadász, C. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01576.x · Cited by 337
Cannabinoids, opioids and eating behavior: The molecular face of hedonism?
Cota, D., Tschöp, M. H., Horvath, T. L., & Levine, A. S. (2006) · Brain Research Reviews · doi:10.1016/j.brainresrev.2005.10.004 · Cited by 330
Endocannabinoids: synthesis and degradation
Marzo, V. D. (2006) · Reviews of physiology, biochemistry and pharmacology · doi:10.1007/112_0505 · Cited by 320
Cannabinoid CB1 Receptor Antagonists as Promising New Medications for Drug Dependence
Foll, B. L., & Goldberg, S. R. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.077974 · Cited by 294
The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders
van der Stelt, M., & Marzo, V. D. (2003) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2003.08.101 · Cited by 292
Leptin Resistance and Obesity
Enriori, P. J., Evans, A. E., Sinnayah, P., & Cowley, M. A. (2006) · Obesity · doi:10.1038/oby.2006.319 · Cited by 281
Endocannabinoid release from midbrain dopamine neurons: a potential substrate for cannabinoid receptor antagonist treatment of addiction
Lupica, C. R., & Riegel, A. C. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.03.016 · Cited by 268
Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents
Griebel, G., Stemmelin, J., & Scatton, B. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.10.032 · Cited by 253
Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716)
Cohen, C., Perrault, G., Griebel, G., & Soubrié, P. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300541 · Cited by 251
The endocannabinoid system in brain reward processes
Solinas, M., Goldberg, S. R., & Piomelli, D. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.130 · Cited by 251
Pharmacotherapy for Nicotine Dependence
Henningfield, J. E., Fant, R. V., Buchhalter, A. R., & Stitzer, M. L. (2005) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.5.281 · Cited by 232
Nicotine induces conditioned place preferences over a large range of doses in rats
Foll, B. L., & Goldberg, S. R. (2004) · Psychopharmacology · doi:10.1007/s00213-004-2021-5 · Cited by 229
Anandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rats
Solinas, M., Justinová, Z., Goldberg, S. R., & Tanda, G. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03880.x · Cited by 234
Tobacco addiction
Hatsukami, D. K., Stead, L. F., & Gupta, P. C. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60871-5 · Cited by 227
REVIEW: Alcohol‐related genes: contributions from studies with genetically engineered mice
Crabbe, J. C., Phillips, T. J., Harris, R. A., Arends, M. A., & Koob, G. F. (2006) · Addiction Biology · doi:10.1111/j.1369-1600.2006.00038.x · Cited by 225
Cannabinoids in health and disease
Kogan, N. M., & Mechoulam, R. (2007) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2007.9.4/nkogan · Cited by 227
Cannabinoid CB1 receptors control conditioned drug seeking
Vries, T. J. D., & Schoffelmeer, A. N. M. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.06.002 · Cited by 219
Braking Dopamine Systems: A New GABA Master Structure for Mesolimbic and Nigrostriatal Functions
Barrot, M., Sesack, S. R., Georges, F. E., Pistis, M., Hong, S., & Jhou, T. C. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.3370-12.2012 · Cited by 229
Marijuana and the Cannabinoids
ElSohly, M. A. (2007) · Humana Press eBooks · doi:10.1007/978-1-59259-947-9 · Cited by 219
Lack of CB1 Cannabinoid Receptor Impairs Cocaine Self-Administration
Sòria, G., Mendizábal, V. E., Touriño, C., Robledo, P., Ledent, C. A., Parmentier, M., Maldonado, R. J., & Valverde, O. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300707 · Cited by 214
A review of co‐morbid tobacco and cannabis use disorders: Possible mechanisms to explain high rates of co‐use
Rabin, R. A., & George, T. P. (2015) · American Journal on Addictions · doi:10.1111/ajad.12186 · Cited by 210
Rapid Changes in Cannabinoid 1 Receptor Availability in Cannabis-Dependent Male Subjects After Abstinence From Cannabis
D’Souza, D. C., Cortes-Briones, J., Ranganathan, M., Thurnauer, H., Creatura, G. M., Surti, T. S., Planeta, B. M., Neumeister, A., Pittman, B. P., Normandin, M. D., et al. (2015) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2015.09.008 · Cited by 204
Cannabidiol reduces cigarette consumption in tobacco smokers: Preliminary findings
Morgan, C. J. A., Das, R., Joye, A., Curran, H. V., & Kamboj, S. K. (2013) · Addictive Behaviors · doi:10.1016/j.addbeh.2013.03.011 · Cited by 194
The Cannabinoid CB1 Antagonist N-Piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl) -4-methylpyrazole-3-carboxamide (SR-141716A) Differentially Alters the Reinforcing Effects of Heroin under Continuous Reinforcement, Fixed Ratio, and Progressive Ratio Schedules of Drug Self-Administration in Rats
Solinas, M., Panlilio, L. V., Antoniou, K., Pappas, L., & Goldberg, S. R. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.047928 · Cited by 194
Effects of Nicotine in Experimental Animals and Humans: An Update on Addictive Properties
Foll, B. L., & Goldberg, S. R. (2009) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-69248-5_12 · Cited by 200
Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression?
Hill, M. N., & Gorzalka, B. B. (2005) · Behavioural Pharmacology · doi:10.1097/00008877-200509000-00006 · Cited by 196
Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors
Serrano, A., & Parsons, L. H. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.06.005 · Cited by 188
Rimonabant, a CB1 antagonist, blocks nicotine-conditioned place preferences
Foll, B. L., & Goldberg, S. R. (2004) · Neuroreport · doi:10.1097/00001756-200409150-00028 · Cited by 178
Endogenous Fatty Acid Ethanolamides Suppress Nicotine-Induced Activation of Mesolimbic Dopamine Neurons through Nuclear Receptors
Melis, M., Pillolla, G., Luchicchi, A., Muntoni, A. L., Yaşar, S., Goldberg, S. R., & Pistis, M. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.3221-08.2008 · Cited by 173
Effect of the cannabinoid CB1 receptor antagonist SR-141716A on ethanol self-administration and ethanol-seeking behaviour in rats
Economidou, D., Mattioli, L., Cifani, C., Perfumi, M. C., Massi, M., Cuomo, V., Trabace, L., & Ciccocioppo, R. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0199-9 · Cited by 169
Nicotine Gateway Effects on Adolescent Substance Use
Ren, M., & Lotfipour, S. (2019) · Western Journal of Emergency Medicine · doi:10.5811/westjem.2019.7.41661 · Cited by 166
Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users
Huestis, M. A., Boyd, S. J., Heishman, S. J., Preston, K. L., BONNET, D., Fur, G. L., & Gorelick, D. A. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0861-5 · Cited by 165
Cannabinoid–Dopamine Interaction in the Pathophysiology and Treatment of CNS Disorders
Fernández‐Ruíz, J., Hernández, M., & Ramos, J. A. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00144.x · Cited by 163
Keynote review: Medicinal chemistry strategies to CB1 cannabinoid receptor antagonists
Lange, J. H. M., & Kruse, C. G. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03427-6 · Cited by 160
Translational research in medication development for nicotine dependence
Lerman, C. E., LeSage, M. G., Perkins, K. A., O’Malley, S. S., Siegel, S. J., Benowitz, N. L., & Corrigall, W. A. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2361 · Cited by 150
Treatment of nicotine addiction: present therapeutic options and pipeline developments
Polosa, R., & Benowitz, N. L. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.12.008 · Cited by 135
Neurobiological mechanisms involved in nicotine dependence and reward: participation of the endogenous opioid system
Berrendero, F., Robledo, P., Trigo, J. M., Martín-García, E., & Maldonado, R. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.02.006 · Cited by 140
Inhibition of Anandamide Hydrolysis by Cyclohexyl Carbamic Acid 3′-Carbamoyl-3-yl Ester (URB597) Reverses Abuse-Related Behavioral and Neurochemical Effects of Nicotine in Rats
Scherma, M., Panlilio, L. V., Fadda, P., Fattore, L., Gamaleddin, I., Foll, B. L., Justinová, Z., Mikics, É., Haller, J., Medalie, J., et al. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.142224 · Cited by 139
The cannabinoid antagonist SR 141716A (Rimonabant) reduces the increase of extra-cellular dopamine release in the rat nucleus accumbens induced by a novel high palatable food
Melis, T., Succu, S., Sanna, F., Boi, A., Argiolas, A., & Melis, M. R. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2007.04.012 · Cited by 138
Nicotine as a typical drug of abuse in experimental animals and humans
Foll, B. L., & Goldberg, S. R. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0155-8 · Cited by 133
Recent advances in understanding nicotinic receptor signaling mechanisms that regulate drug self-administration behavior
Tuesta, L. M., Fowler, C. D., & Kenny, P. J. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.06.026 · Cited by 135
Update on Pharmacologic Options for Smoking Cessation Treatment
Nides, M. A. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.01.016 · Cited by 130
The Endocannabinoid System and Cannabidiol's Promise for the Treatment of Substance Use Disorder
Chye, Y., Christensen, E., Solowij, N., & Yücel, M. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00063 · Cited by 132
Reduced Brain Cannabinoid Receptor Availability in Schizophrenia
Ranganathan, M., Cortes-Briones, J., Radhakrishnan, R., Thurnauer, H., Planeta, B. M., Skosnik, P. D., Gao, H., Labaree, D. C., Neumeister, A., Pittman, B. P., et al. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.08.021 · Cited by 124
Endocannabinoid signaling and food addiction
D’Addario, C., Bonaventura, M. V. M. D., Pucci, M., Romano, A., Gaetani, S., Ciccocioppo, R., Cifani, C., & Maccarrone, M. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.08.008 · Cited by 124
The α4β2 nicotinic acetylcholine-receptor partial agonist varenicline inhibits both nicotine self-administration following repeated dosing and reinstatement of nicotine seeking in rats
O’Connor, E. C., Parker, D., Rollema, H., & Mead, A. N. (2010) · Psychopharmacology · doi:10.1007/s00213-009-1739-5 · Cited by 118
Role of CB2 Cannabinoid Receptors in the Rewarding, Reinforcing, and Physical Effects of Nicotine
Navarrete, F., Rodríguez‐Arias, M., Martín‐García, E., Navarro, D., García‐Gutiérrez, M. S., Aguilar, M. A., Aracil-Fernández, A., Berbel, P. J., Miñarro, J., Maldonado, R. J., et al. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.157 · Cited by 122
Metabolic consequences of hyperglycemia and insulin resistance
Jellinger, P. S. (2007) · Clinical cornerstone · doi:10.1016/s1098-3597(07)80019-6 · Cited by 121
CB receptor antagonists for the treatment of nicotine addiction
Cohen, C., Kodas, E., & Griebel, G. (2005) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2005.01.024 · Cited by 123
Inhibition of fatty acid amide hydrolase reduces reinstatement of nicotine seeking but not break point for nicotine self-administration—comparison with CB1 receptor blockade
Forget, B., Coen, K. M., & Foll, B. L. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1569-5 · Cited by 121
Blockade of Nicotine Reward and Reinstatement by Activation of Alpha-Type Peroxisome Proliferator-Activated Receptors
Mascia, P., Pistis, M., Justinová, Z., Panlilio, L. V., Luchicchi, A., Lecca, S., Scherma, M., Fratta, W., Fadda, P., Barnes, C., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.07.009 · Cited by 124
The fatty acid amide hydrolase C385A (P129T) missense variant in cannabis users: studies of drug use and dependence in Caucasians.
Tyndale, R. F., Payne, J. I., Gerber, A. L., & Sipe, J. C. (2007) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30491 · Cited by 117
Role of the endocannabinoid system in drug addiction
Manzanares, J., Cabañero, D., Puente, N., García‐Gutiérrez, M. S., Grandes, P., & Maldonado, R. J. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.09.013 · Cited by 118
SR147778 [5-(4-Bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1 H-pyrazole-3-carboxamide], a New Potent and Selective Antagonist of the CB1 Cannabinoid Receptor: Biochemical and Pharmacological Characterization
Rinaldi, M. L., Barth, F., Congy, C., Martinez, S., Oustric, D., Perio, A., Poncelet, M., Maruani, J., Arnone, M., Finance, O., et al. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.067884 · Cited by 115
Δ9‐tetrahydrocannabinol decreases somatic and motivational manifestations of nicotine withdrawal in mice
Balerio, G. N., Aso, E., Berrendero, F., Murtra, P., & Maldonado, R. J. (2004) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2004.03714.x · Cited by 118
Cannabinoid CB1 antagonists and dopamine antagonists produce different effects on a task involving response allocation and effort-related choice in food-seeking behavior
Sink, K. S., Vemuri, K. V., Olszewska, T., Makriyannis, A., & Salamone, J. D. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0988-4 · Cited by 115
Cannabinoid CB1 receptors are involved in motivational effects of nicotine in rats
Forget, B., Hamon, M., & Thiébot, M.-H. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0015-6 · Cited by 116
Endocannabinoid system and alcohol addiction: Pharmacological studies
Colombo, G., SERRA, S., VACCA, G., Carai, M. A. M., & GESSA, G. L. (2005) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2005.01.022 · Cited by 114
Transdermal nicotine alters some of marihuana's effects in male and female volunteers
Penetar, D. M., Kouri, E. M., Gross, M. M., McCarthy, E. M., Rhee, C. K., Peters, E. N., & Lukas, S. E. (2005) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2005.01.008 · Cited by 115
SSR591813, a Novel Selective and Partial α4β2 Nicotinic Receptor Agonist with Potential as an Aid to Smoking Cessation
Cohen, C., Bergis, O. E., Galli, F., Lochead, A. W., Jegham, S., Biton, B., Léonardon, J., Avenet, P., Sgard, F., Besnard, F., et al. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.049262 · Cited by 114
The peripheral cannabinoid receptor knockout mice: an update
Buckley, N. E. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707527 · Cited by 115
Endocannabinoid system and opioid addiction: Behavioural aspects
Fattore, L., Deiana, S., Spano, S., Cossu, G., Fadda, P., Scherma, M., & Fratta, W. (2005) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2005.01.031 · Cited by 113
An endocannabinoid mechanism in relapse to drug seeking: A review of animal studies and clinical perspectives
Fattore, L., Spano, M. S., Deiana, S., Melis, V., Cossu, G., Fadda, P., & Fratta, W. (2006) · Brain Research Reviews · doi:10.1016/j.brainresrev.2006.05.003 · Cited by 110
Inhibition of FAAH and activation of PPAR: New approaches to the treatment of cognitive dysfunction and drug addiction
Panlilio, L. V., Justinová, Z., & Goldberg, S. R. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.003 · Cited by 106
Advances in pharmacotherapy for tobacco dependence
Foulds, J., Burke, M. V., Steinberg, M. B., Williams, J. M., & Ziedonis, D. M. (2004) · Expert Opinion on Emerging Drugs · doi:10.1517/eoed.9.1.39.32951 · Cited by 107
Blocking cannabinoid CB1receptors for the treatment of nicotine dependence: insights from pre‐clinical and clinical studies
Foll, B. L., Forget, B., Aubin, H., & Goldberg, S. R. (2008) · Addiction Biology · doi:10.1111/j.1369-1600.2008.00113.x · Cited by 108
Role of the cannabinoid system in the effects induced by nicotine on anxiety-like behaviour in mice
Balerio, G. N., Aso, E., & Maldonado, R. J. (2006) · Psychopharmacology · doi:10.1007/s00213-005-0251-9 · Cited by 104
Suppression of conditioned nicotine and sucrose seeking by the cannabinoid-1 receptor antagonist SR141716A
Vries, T. J. D., de Vries, W., Janssen, M. C. W., & Schoffelmeer, A. N. M. (2005) · Behavioural Brain Research · doi:10.1016/j.bbr.2005.02.021 · Cited by 102
Nicotine-Induced Changes in Neurotransmitter Levels in Brain Areas Associated with Cognitive Function
Singer, S., Rossi, S., Verzosa, S., Hashim, A. T., Lonow, R., Cooper, T. B., Sershen, H. W., & Lajtha, Á. (2004) · Neurochemical Research · doi:10.1023/b:nere.0000035814.45494.15 · Cited by 98
The Neuronal Pathways Mediating the Behavioral and Addictive Properties of Nicotine
Balfour, D. J. K. (2009) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-540-69248-5_8 · Cited by 99
Prior Exposure to THC Increases the Addictive Effects of Nicotine in Rats
Panlilio, L. V., Zanettini, C., Barnes, C., Solinas, M., & Goldberg, S. R. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.16 · Cited by 97
Control of the reinforcing effects of nicotine by associated environmental stimuli in animals and humans
Foll, B. L., & Goldberg, S. R. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.04.005 · Cited by 102
Endocannabinoid system involvement in brain reward processes related to drug abuse
Solinas, M., Yaşar, S., & Goldberg, S. R. (2007) · Pharmacological Research · doi:10.1016/j.phrs.2007.09.005 · Cited by 102
Changes in endocannabinoid levels in a rat model of behavioural sensitization to morphine
Viganò, D., Valenti, M., Cascio, M. G., Marzo, V. D., Parolaro, D., & Rubino, T. (2004) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2004.03645.x · Cited by 97
Neuropharmacology and potential efficacy of new treatments for tobacco dependence
Fagerström, K. O., & Balfour, D. J. K. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.2.107 · Cited by 95
The cannabinoid antagonist AM251 attenuates nicotine self-administration and nicotine-seeking behaviour in rats
Shoaib, M. C. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.10.011 · Cited by 93
Why Should We Keep the Cerebellum in Mind When Thinking About Addiction?
Miquel, M., Toledo‐Cárdenas, M. R., García, L. I., Coria‐Ávila, G. A., & Manzo, J. (2009) · Current Drug Abuse Reviews · doi:10.2174/1874473710902010026 · Cited by 96
The role of CB1 receptors in psychostimulant addiction
Wiskerke, J., Pattij, T., Schoffelmeer, A. N. M., & Vries, T. J. D. (2008) · Addiction Biology · doi:10.1111/j.1369-1600.2008.00109.x · Cited by 91
Cannabinoid receptor stimulation increases motivation for nicotine and nicotine seeking
Gamaleddin, I., Wertheim, C. E., Zhu, A. Z. X., Coen, K. M., Vemuri, K. V., Makryannis, A., Goldberg, S. R., & Foll, B. L. (2011) · Addiction Biology · doi:10.1111/j.1369-1600.2011.00314.x · Cited by 94
Ethanol Self‐Administration Is Regulated by CB1 Receptors in the Nucleus Accumbens and Ventral Tegmental Area in Alcohol‐Preferring AA Rats
Malinen, H., & Hyytiä, P. (2008) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2008.00786.x · Cited by 96
Interactions between nicotine and drugs of abuse: a review of preclinical findings
Kohut, S. J. (2016) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2016.1209513 · Cited by 91
Rimonabant: The first therapeutically relevant cannabinoid antagonist
Carai, M. A. M., Colombo, G., & Gessa, G. L. (2005) · Life Sciences · doi:10.1016/j.lfs.2005.04.017 · Cited by 90
Habitual alcohol seeking: Modeling the transition from casual drinking to addiction
Barker, J. M., & Taylor, J. R. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.08.012 · Cited by 89
The endocannabinoid system as a target for addiction treatment: Trials and tribulations
Sloan, M. E., Gowin, J. L., Ramchandani, V. A., Hurd, Y. L., & Foll, B. L. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.05.031 · Cited by 94
Reduced neural response to reward following 7 days treatment with the cannabinoid CB1 antagonist rimonabant in healthy volunteers
Horder, J., Harmer, C. J., Cowen, P. J., & McCabe, C. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710000453 · Cited by 89
Treating Tobacco Dependence: State of the Science and New Directions
Lerman, C. E., Patterson, F., & Berrettini, W. H. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.058 · Cited by 85
Blockade of THC-Seeking Behavior and Relapse in Monkeys by the Cannabinoid CB1-Receptor Antagonist Rimonabant
Justinová, Z., Munzar, P., Panlilio, L. V., Yaşar, S., Redhi, G. H., Tanda, G., & Goldberg, S. R. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.21 · Cited by 86
Pharmacotherapy and Pharmacogenetics of Nicotine Dependence
Berrettini, W. H., & Lerman, C. E. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.8.1441 · Cited by 85
Metabotropic Glutamate Receptor mGlu5 Is a Mediator of Appetite and Energy Balance in Rats and Mice
BRADBURY, M. J., Campbell, U. C., Giracello, D. R., Chapman, D. F., King, C., Tehrani, L. R., Cosford, N. D. P., Anderson, J., Varney, M. A., & Strack, A. M. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.076406 · Cited by 86

Authors: Cohen, C., Perrault, G., Voltz, C., Steinberg, R., & Soubrié, P.
Affiliations: Sanofi (France) (FR)
Corresponding author: Cohen, C.
Venue: Behavioural Pharmacology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2002-09
Volume: 13
Issue: 5
Pages: 451-463
ISSN: 0955-8810 (ISSN-L)
DOI: 10.1097/00008877-200209000-00018
OpenAlex: W2001109168
Cited by: 396
References: 77
Citations by year: 2026: 5 · 2025: 2 · 2024: 4 · 2023: 11 · 2022: 9 · 2021: 7 · 2020: 13 · 2019: 8 · 2018: 8 · 2017: 11 · 2016: 20 · 2015: 14 · 2014: 9 · 2013: 19 · 2012: 16
FWCI: 16.34
Type: journal article
Language: en
Open access: closed
Locations: Behavioural Pharmacology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
Keywords: SR141716, nicotine self-administration, dopamine release, nucleus accumbens shell, bed nucleus of the stria terminalis, endocannabinoid system, drug reward, alcohol consumption reduction, smoking cessation
MeSH terms: Rimonabant, Ethanol, Animals, Brain Chemistry, Central Nervous System Depressants, Discrimination Learning, Dopamine, Extracellular Space, Male, Motivation, Nicotine, Nucleus Accumbens, Piperidines, Pyrazoles, Receptors, Drug, Reinforcement, Psychology, Self Administration, Rats, Sprague-Dawley, Rats, Wistar, Microdialysis, Nicotinic Agonists, Nicotinic Antagonists, Receptors, Cannabinoid, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

SR141716, a central cannabinoid (CB1) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks